Osteoarthritis, KneeNCT03281837
2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)
A study testing HYMOVIS plus Physical Exercise Program (PEP) and Physical Exercise Program (PEP) alone in people with Osteoarthritis, Knee and Knee Osteoarthritis, run by Fidia Pharma USA Inc. at 10 sites in United States.
Trial summary
Knee osteoarthritis (OA) is among the most common causes of musculoskeletal pain and disability. At present, there is no cure for OA. Therefore, the primary aims of therapy are to reduce pain, maintain or improve function and mobility, and prevent or slow the progression of adverse changes to the joint tissues, while… Read more about this study
- Who is it for?
- Ages 21 to 60 years
- Conditions the study is for
- Osteoarthritis, Knee, Knee Osteoarthritis, Patellofemoral Osteoarthritis
- What is being tested?
- HYMOVIS plus Physical Exercise Program (PEP) and Physical Exercise Program (PEP) alone
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 148 participants
- Where
- 10 sitesUnited States
- Study dates
- 1 Oct 2017to 16 Jul 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male or female ≥21 years and ≤60 years old and with BMI ≤40
- Moderate to severe knee OA pain ≥3 and ≤8 on the NRS pain subscale in the affected knee (signal knee)
- Mild or no pain ≤3 on the numeric rating scale (NRS) pain subscale in the contralateral knee (unaffected knee)
- Persistent knee pain lasting at least 3 months prior to Screening
- Active life-style (play or train themselves at least 2 to 3 times per week)
- Diagnosis of knee OA confirmed by radiographic assessment (must be performed within 6 months prior to screening visit):
Show all 11Show fewer
- anterior-posterior view (weight bearing extension or semi-flexion) of tibiofemoral joint, (posterior-anterior/Rosenberg view as an additional alternate)
- lateral view of both the tibiofemoral and patellofemoral joints
- Merchant X-ray (or Sunrise) view for patellofemoral joint.
- Radiographic assessment must confirm K-L Grade 1 to 3 for TFOA and/or K-L Grade 1 to for PFOA.
- Radiographic assessment confirms normal articulation of patella and trochlea in Merchant (or Sunrise) view
Who cannot join
- Radiographic assessment confirms abnormal patellofemoral tracking or articulation in lateral and/or Merchant view (or Sunrise View)
- Major injury to or disorder of the contralateral knee or other weight-bearing joint that would interfere with the study assessments.
- Secondary OA of the study joint due to a prior or concomitant condition (e.g., septic arthritis, inflammatory joint disease, gout, articular fracture, major dysplasia, or congenital abnormality, hemochromatosis, etc.).
- Surgery to the study joint within the previous 12 months prior to Screening. Surgery to the contralateral knee or other weight-bearing joint within the previous 12 months that would interfere with the study assessments.
- Patients with either total joint replacement implants, unicondylar implants or patellofemoral replacement implants in the affected joint.
- Ligament reconstruction of the affected knee within 3 years.
Show all 50Show fewer
- Inflammatory arthropathies such as rheumatoid arthritis, lupus, or psoriatic arthritis.
- Episode of gout or calcium pyrophosphate (pseudogout) diseases within 6 months prior to Screening.
- IA or local peri-articular corticosteroid injections to the study joint/knee within 8 weeks (2 months) prior to Screening or to any other joint (other than the study joint) or soft tissue area within 1 month prior to Screening.
- Any oral corticosteroid within 1 month prior to Screening. Steroid inhalants are permitted if the Subject has been on a stable regimen for the past 1 month prior to Screening and remains on this regimen throughout the course of the trial.
- Intra-articular HA in the study joint within 6 months prior to Screening.
- History of allergic reaction to an intra-articular Hyaluronic acid injection.
- Known hypersensitivity (allergy) to gram positive bacterial proteins.
- Use of glucosamine or chondroitin sulfate containing products unless the subject is on stable doses for at least 14 days prior to Screening and willing to remain on these stable doses throughout the course of the study.
- Inability to perform the climbing stair test.
- X-ray findings of acute fractures, severe loss of bone density, avascular necrosis and/or severe deformity.
- Axial deviation of the lower limbs greater than 20 degrees in valgus or varus on standing X-ray.
- Symptomatic OA of either hip or spine with a pain score ≥2 on the NRS on or off pain medication.
- Clinically significant medio-lateral and/or anterior-posterior instability.
- Osteonecrosis of either knee.
- Participation in a physical therapy regimen that has not been stable during the 1 month prior to Screening and the subject is unwilling or unable to maintain the same regimen throughout the course of the trial or is unwilling to stop previously prescribed or self-initiated physical therapy regimen and switch solely to and initiate study defined PEP program.
- K-L Grade 4 TFOA of the knee (i.e., large osteophytes, marked narrowing, severe sclerosis, and definite deformity).
- K-L Grade 4 PFOA of the knee (i.e., large osteophytes, marked narrowing, severe sclerosis, definite deformity)
- Hemiparesis of the lower limbs.
- Significant surgery of lower limbs (hip, ankle, foot) that may interfere with knee assessments.
- Chronic use of analgesia for pain (including pain in the other knee or any other joint) that may interfere with the evaluations of the test knee (such as possible use of rescue medication for these other conditions).
- Known allergies to acetaminophen and hyaluronan preparations.
- Know hypersensitivity (allergy) to anesthetics
- Recurrent medical history of severe allergic or immune-mediated reactions.
- Active infection or skin diseases in the area of the potential injection site or joint.
- Any dermatological disease overlying the signal joint that would contraindicate multiple injections or aspirations.
- Use of any agent reported to have symptom relief for arthritis or be a disease/structure modifying drug (e.g. doxycycline, long-term tetracycline, s-adenosylmethionine [SAM], methylsulfonylmethane [MSM] or dimethylsulfoxide [DMSO], dietary supplements or any herbal remedy taken for arthritic and joint conditions within the past month (exceptions as specified in Exclusion #14).
- Peripheral neuropathy that would be severe enough to interfere with the evaluation of the subject.
- Psychological status (e.g., anxiety, depression, poor sleep quality, pain catastrophizing, etc.) that may interfere with functional assessment of the target knee.
- Vascular insufficiency of lower limbs that is severe enough to interfere with the evaluation of the subject.
- Concomitant therapy with anticoagulants (low dose aspirin, not exceeding 325 mg per day as an anti-thrombotic agent is permitted if stable for 1 month prior to Screening and remains stable throughout the study).
- Any concomitant disease(s) or condition(s) that may interfere with the free use and evaluation of the affected knee for the 6 months course of the trial (cancer, other rheumatic diseases, gout, severe congenital defects, etc.).
- Any serious mobility problems (e.g. Parkinson's disease) or claustrophobia
- Any concomitant chronic disease(s) or condition(s) that may predispose them to a high probability of interfering with the completion of the 6-month follow-up of the study such as peptic ulcer, liver disease, severe coronary disease, renal disease, cancer, pregnancy, alcoholism, drug abuse, mental state, or other clinically significant condition.
- Excessive alcohol consumption or alcoholism that would be contraindicated with the use of acetaminophen.
- Use of marijuana, whether prescribed or not
- Any clinically significant diagnostic test and/or abnormal laboratory test result(s) that, in the opinion of the clinical investigator, may place the subject's health at risk, impact the study, or impact the subject's ability to complete the study.
- Inability to legally comprehend the details and nature of the study for any reason, including psychiatric illness.
- Likelihood of protocol violations or unlikely to compete the study for any reason, as determined by the clinical investigator.
- Continued participation in an experimental drug/device study or any clinical trial within the previous 8 weeks prior to Screening. Subjects must have fully completed participation in an experimental drug/device study of any clinical trial at least 8 weeks prior to screening.
- Pregnancy, breastfeeding, planned conception, premenopausal women who have not had tubal ligation, hysterectomy, or are unwilling or unable to utilize contraceptive measures (or contraception)
- Prior history of any malignancy with the exception of basal cell carcinoma of the skin treated more than 2 years prior to Screening.
- Significant bleeding diathesis.
- Participation in current litigation for injuries related to the study knee or other injuries that might interfere with their completion of the study protocol.
- Non-English speaking subjects.
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
United States10 sites
IntegraTrials LLC / OrthoVirginia
Arlington, Virginia, 22205
CORE Orthopaedic Medical Center
Encinitas, California, 92024
Cartilage Research Foundation, Inc. - OrthoIndy
Greenwood, Indiana, 46143
Andrews Institute Orthopaedics and Sports Medicine - Andrews Research & Education Foundation
Gulf Breeze, Florida, 32561
Kerlan-Jobe Orthopaedic Clinic
Los Angeles, California, 90045
Cedars-Sinai Medical Center
Los Angeles, California, 90048
New York University - Center for Musculoskeletal Care
New York, New York, 10016
Hospital for Special Surgery
New York, New York, 10021
Horizon Clinical Research / Grossmont Orthopaedic Medical Group
San Diego, California, 91942
Tucson Orthopaedic Institute Research Center
Tucson, Arizona, 85712
About this study
Official title: A Post-market, Single Blind, Multicenter, Randomized, Controlled Trial of HYMOVIS® Intra-articular Injections in Active Subjects With Knee Osteoarthritis
Knee osteoarthritis (OA) is among the most common causes of musculoskeletal pain and disability. At present, there is no cure for OA. Therefore, the primary aims of therapy are to reduce pain, maintain or improve function and mobility, and prevent or slow the progression of adverse changes to the joint tissues, while keeping potential therapeutic toxicities to a minimum. Current treatment guidelines begin with non-pharmacologic modalities, such as patient education, weight loss, and physical therapy. Several exercise-based therapeutic approaches, such as aerobic exercise programs, range-of-motion exercises, and muscle-strengthening exercises are recommended and have shown clinical benefit in randomized, controlled clinical trials. However, non-pharmacologic approaches frequently provide insufficient pain relief and restoration of function and mobility, and pharmacologic modalities become necessary. Although simple analgesics such as acetaminophen provide relief for many OA subjects with mild to moderate pain, alternatives should be considered for subjects who fail to obtain adequate symptomatic relief with these measures.
This post-market, single blind, multicenter, randomized, controlled clinical study is designed to enroll a relatively young, active population of subjects with patellofemoral osteoarthritis (PFOA) and/or tibiofemoral osteoarthritis (TFOA), and to compare responses to treatment with 2 weekly intra-articular (IA) hyaluronan (HA) injections, with each injection given 1 week apart, of HYMOVIS combined with a physical exercise program (PEP) to PEP alone. Because PEP or exercise programs may be considered the first line standard of care in OA knee pain, particularly in younger, active patients, the hypothesis of the study is that Hymovis combined with PEP program provides greater relief of pain associated with knee OA in the enrolled study subjects than with use of PEP alone.
Read more
The study provides for subjects randomized to the PEP alone study group to cross over to HYMOVIS+PEP if improvement has not been achieved by the 3 month follow up visit.
Subjects will be recruited over an 18 month period. The duration of the trial per center will be approximately 27 months. This includes the enrollment period of 6 months, the follow-up period at 3 and 6 months and the additional follow-up period for patients who crossed-over; they will be followed for an additional 6 months following the initial 3month follow-up. The trial will end when the last subject makes the last visit.
- Being tested
- HYMOVIS plus Physical Exercise Program (PEP), Physical Exercise Program (PEP) alone
- Keywords
- osteoarthritis, knee osteoarthritis, patellofemoral osteoarthritis, tibiofemoral osteoarthritis, hyaluronan, hyaluronic acid, intra-articular, arthritis, joint disease, active, viscosupplements, Hymovis
- Medical subject headings
- Osteoarthritis, Knee, Osteoarthritis, Arthritis, Joint Diseases, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HYMOVIS plus Physical Exercise Program (PEP)Device
1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
Physical Exercise Program (PEP) aloneOther
Physical Exercise Program (PEP) alone for at least 8 weeks
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Hymovis plus Physical Exercise Program (PEP) | Experimental | Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP) Receives: Device: HYMOVIS plus Physical Exercise Program (PEP) |
| Group 2: Physical Exercise Program (PEP) alone alone | Other | Specified designed Physical Exercise Program (PEP) not combined with any other intervention Receives: Other: Physical Exercise Program (PEP) alone |
| Group 3: Cross-Over group | Other | Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis. Receives: Device: HYMOVIS plus Physical Exercise Program (PEP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in average score for 4 of the 5 Knee Injury and Osteoarthritis Outcome Score subscales (KOOS) over 3 months from baseline (Day 90). Scores to be measured are pain, symptoms, function in sport and recreation, and knee related quality of life.
Measured: Baseline and 90 days after baseline
Secondary outcomes (7)
Safety - Number of participants with intervention / treatment-related adverse events
The investigator's determination and term of each adverse event (AE) will be mapped to system organ class and preferred term using the MedDRA dictionary. Incidence and frequency of AE's will be summarized for each treatment group by MedDRA system organ class and preferred term. A subject will only be counted once per system organ class and once per preferred term within a treatment. The summaries will include: All adverse events, All adverse events by severity, All adverse events by relationship to the study device, All adverse device effects, All adverse events leading to discontinuation from study
Measured: Baseline, 30 days, 60 days, 90 days, 120 days, 150 days, 180 days, through study completion (1 year)
Time to onset and duration of pain relief at all post-baseline points for the duration of the study
Measured: Baseline, 30 days, 60 days, 90 days, 120 days, 150 days, 180 days, through study completion (1 year)
Number of subjects achieving pain-free or disability-free return to sports over the duration of the study
Measured: Baseline, 30 days, 60 days, 90 days, 120 days, 150 days, 180 days, through study completion (1 year)
Analysis on the need for rescue analgesic medication for pain relief
Measured: Baseline, 30 days, 60 days, 90 days, 120 days, 150 days, 180 days, through study completion (1 year)
Global assessments and SF-12 conducted by the clinicians and self-reported by the subjects
Measured: Baseline, 90 days, 180 days, through study completion (1 year)
Number of subjects continuing to cross-over phase of study due to failure to respond adequately to PEP alone
Measured: Baseline, 90 days, 180 days, through study completion (1 year)
Biochemical serum biomarker analysis.
Measured: Baseline, 90 days, 180 days, through study completion (1 year)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Sep 2017
- Study start1 Oct 2017
- Primary completion9 Jul 2020
- Study completion16 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Osteoarthritis, KneeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This post-market, single blind, multicenter, randomized, controlled clinical study is designed to enroll a relatively young, active population of subjects with patellofemoral osteoarthritis (PFOA) and/or tibiofemoral osteoarthritis (TFOA), and to compare responses to treatment with HYMOVIS injections combined with a physical exercise program (PEP) to PEP alone. The study provides for subjects randomized to the PEP alone study group to cross over to HYMOVIS+PEP if improvement has not been achieved by the 3 month follow up visit. Subjects will be recruited over a 18 month period. The duration of the trial per center will be approximately 27 months. This includes the enrollment period of 6 months, the follow-up period at 3 and 6 months and the additional follow-up period for patients who crossed-over; they will be followed for an additional 6 months following the initial 3month follow-up. The trial will end when the last subject makes the last visit.
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 148 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fidia Pharma USA Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Cedars-Sinai Medical Center, Principal investigator, Cedars-Sinai Medical Center - Department of Orthopaedic SurgeryKerlan-Jobe Orthopaedic Clinic, Principal investigator, Kerlan-Jobe Orthopaedic Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03281837
- Sponsor's protocol ID
- EQE7-16-01
- Status last verified
- Jul 2020
- First submitted
- 8 Sep 2017
- Last updated
- 21 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Post-market, Single Blind, Multicenter, Randomized, Controlled Trial of HYMOVIS® Intra-articular Injections in Active Subjects With Knee Osteoarthritis
- ClinicalTrials.gov ID
- NCT03281837
- Acronym / sponsor ID
- EQE7-16-01
- Keywords
- osteoarthritis, knee osteoarthritis, patellofemoral osteoarthritis, tibiofemoral osteoarthritis, hyaluronan, hyaluronic acid, intra-articular, arthritis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 148 participants (actual)
- Lead sponsor
- Fidia Pharma USA Inc.Industry (pharma, biotech, devices)
- Study start
- 1 Oct 2017 (actual)
- Primary completion
- 9 Jul 2020 (actual)
- Study completion
- 16 Jul 2020 (actual)
- First posted
- 13 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Knee osteoarthritis (OA) is among the most common causes of musculoskeletal pain and disability. At present, there is no cure for OA. Therefore, the primary aims of therapy are to reduce pain, maintain or improve function and mobility, and prevent or slow the progression of adverse changes to the joint tissues, while keeping potential therapeutic toxicities to a minimum. Current treatment guidelines begin with non-pharmacologic modalities, such as patient education, weight loss, and physical therapy. Several exercise-based therapeutic approaches, such as aerobic exercise programs, range-of-motion exercises, and muscle-strengthening exercises are recommended and have shown clinical benefit in randomized, controlled clinical trials. However, non-pharmacologic approaches frequently provide insufficient pain relief and restoration of function and mobility, and pharmacologic modalities become necessary. Although simple analgesics such as acetaminophen provide relief for many OA subjects with mild to moderate pain, alternatives should be considered for subjects who fail to obtain adequate symptomatic relief with these measures.
This post-market, single blind, multicenter, randomized, controlled clinical study is designed to enroll a relatively young, active population of subjects with patellofemoral osteoarthritis (PFOA) and/or tibiofemoral osteoarthritis (TFOA), and to compare responses to treatment with 2 weekly intra-articular (IA) hyaluronan (HA) injections, with each injection given 1 week apart, of HYMOVIS combined with a physical exercise program (PEP) to PEP alone. Because PEP or exercise programs may be considered the first line standard of care in OA knee pain, particularly in younger, active patients, the hypothesis of the study is that Hymovis combined with PEP program provides greater relief of pain associated with knee OA in the enrolled study subjects than with use of PEP alone.
The study provides for subjects randomized to the PEP alone study group to cross over to HYMOVIS+PEP if improvement has not been achieved by the 3 month follow up visit.
Subjects will be recruited over an 18 month period. The duration of the trial per center will be approximately 27 months. This includes the enrollment period of 6 months, the follow-up period at 3 and 6 months and the additional follow-up period for patients who crossed-over; they will be followed for an additional 6 months following the initial 3month follow-up. The trial will end when the last subject makes the last visit.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- This post-market, single blind, multicenter, randomized, controlled clinical study is designed to enroll a relatively young, active population of subjects with patellofemoral osteoarthritis (PFOA) and/or tibiofemoral osteoarthritis (TFOA), and to compare responses to treatment with HYMOVIS injections combined with a physical exercise program (PEP) to PEP alone. The study provides for subjects randomized to the PEP alone study group to cross over to HYMOVIS+PEP if improvement has not been achieved by the 3 month follow up visit. Subjects will be recruited over a 18 month period. The duration of the trial per center will be approximately 27 months. This includes the enrollment period of 6 months, the follow-up period at 3 and 6 months and the additional follow-up period for patients who crossed-over; they will be followed for an additional 6 months following the initial 3month follow-up. The trial will end when the last subject makes the last visit.
| Arm | Type | Receives |
|---|---|---|
| Group 1: Hymovis plus Physical Exercise Program (PEP) | Experimental | Device: HYMOVIS plus Physical Exercise Program (PEP)Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP) |
| Group 2: Physical Exercise Program (PEP) alone alone | Other | Other: Physical Exercise Program (PEP) aloneSpecified designed Physical Exercise Program (PEP) not combined with any other intervention |
| Group 3: Cross-Over group | Other | Device: HYMOVIS plus Physical Exercise Program (PEP)Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis. |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Male or female ≥21 years and ≤60 years old and with BMI ≤40
- Moderate to severe knee OA pain ≥3 and ≤8 on the NRS pain subscale in the affected knee (signal knee)
- Mild or no pain ≤3 on the numeric rating scale (NRS) pain subscale in the contralateral knee (unaffected knee)
- Persistent knee pain lasting at least 3 months prior to Screening
- Active life-style (play or train themselves at least 2 to 3 times per week)
Key exclusion criteria (50 listed)
- Radiographic assessment confirms abnormal patellofemoral tracking or articulation in lateral and/or Merchant view (or Sunrise View)
- Major injury to or disorder of the contralateral knee or other weight-bearing joint that would interfere with the study assessments.
- Secondary OA of the study joint due to a prior or concomitant condition (e.g., septic arthritis, inflammatory joint disease, gout, articular fracture, major dysplasia, or congenital abnormality, hemochromatosis, etc.).
- Surgery to the study joint within the previous 12 months prior to Screening. Surgery to the contralateral knee or other weight-bearing joint within the previous 12 months that would interfere with the study assessments.
- Patients with either total joint replacement implants, unicondylar implants or patellofemoral replacement implants in the affected joint.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HYMOVIS plus Physical Exercise Program (PEP)1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP) | Device | Group 1: Hymovis plus Physical Exercise Program (PEP), Group 3: Cross-Over group |
| Physical Exercise Program (PEP) alonePhysical Exercise Program (PEP) alone for at least 8 weeks | Other | Group 2: Physical Exercise Program (PEP) alone alone |
Primary outcome
Improvement in average score for 4 of the 5 Knee Injury and Osteoarthritis Outcome Score subscales (KOOS) over 3 months from baseline (Day 90). Scores to be measured are pain, symptoms, function in sport and recreation, and knee related quality of life.
Time frame: Baseline and 90 days after baseline
7 secondary outcomes
Safety - Number of participants with intervention / treatment-related adverse events
Time frame: Baseline, 30 days, 60 days, 90 days, 120 days, 150 days, 180 days, through study completion (1 year)
Time to onset and duration of pain relief at all post-baseline points for the duration of the study
Time frame: Baseline, 30 days, 60 days, 90 days, 120 days, 150 days, 180 days, through study completion (1 year)
Number of subjects achieving pain-free or disability-free return to sports over the duration of the study
Time frame: Baseline, 30 days, 60 days, 90 days, 120 days, 150 days, 180 days, through study completion (1 year)
Analysis on the need for rescue analgesic medication for pain relief
Time frame: Baseline, 30 days, 60 days, 90 days, 120 days, 150 days, 180 days, through study completion (1 year)
Global assessments and SF-12 conducted by the clinicians and self-reported by the subjects
Time frame: Baseline, 90 days, 180 days, through study completion (1 year)
Number of subjects continuing to cross-over phase of study due to failure to respond adequately to PEP alone
Time frame: Baseline, 90 days, 180 days, through study completion (1 year)
Biochemical serum biomarker analysis.
Time frame: Baseline, 90 days, 180 days, through study completion (1 year)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2020.
- Individual participant dataSharing planned: Undecided
Related trials for Osteoarthritis, Knee
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cedars-Sinai Medical Center principal investigator
Cedars-Sinai Medical Center - Department of Orthopaedic Surgery
Kerlan-Jobe Orthopaedic Clinic principal investigator
Kerlan-Jobe Orthopaedic Clinic
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HYMOVIS plus Physical Exercise Program (PEP) and Physical Exercise Program (PEP) alone in people with Osteoarthritis, Knee and Knee Osteoarthritis, run by Fidia Pharma USA Inc. at 10 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 50 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in average score for 4 of the 5 Knee Injury and Osteoarthritis Outcome Score subscales (KOOS) over 3 months from baseline (Day 90). Scores to be measured are pain, symptoms, function in sport and recreation, and knee related quality of life. (time frame: Baseline and 90 days after baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2020.